Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Which test is best for chlamydia?

J Schachter1

  • 1Department of Laboratory Medicine, University of California, San Francisco, CA 94143, USA. jsch@itsa.ucsf.edu

Current Opinion in Infectious Diseases
|October 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same journal

Use of gloves: current evidence vs. current use.

Current opinion in infectious diseases·2026
Same journal

Understanding challenges to prevention of healthcare related infections.

Current opinion in infectious diseases·2026
Same journal

Harnessing next-generation microbial diagnostics to optimize infection management in immunocompromised hosts.

Current opinion in infectious diseases·2026
Same journal

Epidemiology, treatment and outcomes of antimicrobial-resistant infections in hematopoietic stem cell transplant recipients.

Current opinion in infectious diseases·2026
Same journal

Dengue and chikungunya vaccines past, present and future: implications for travelers.

Current opinion in infectious diseases·2026
Same journal

Oropouche virus: viral evolution, epidemiological trends, and challenges for control.

Current opinion in infectious diseases·2026
See all related articles

Nucleic acid amplification tests are the preferred method for diagnosing Chlamydia trachomatis infections. These sensitive tests offer a non-invasive way to detect genital chlamydial infection using urine or vaginal swabs.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Diagnostic Testing

Background:

  • Chlamydia trachomatis is a common bacterial cause of sexually transmitted infections.
  • Traditional diagnostic methods, such as tissue culture, have limitations in sensitivity.
  • There is a need for more accurate and accessible diagnostic tools.

Purpose of the Study:

  • To highlight the advantages of nucleic acid amplification tests (NAATs) for Chlamydia trachomatis diagnosis.
  • To compare the sensitivity of NAATs with traditional methods like tissue culture.
  • To assess the feasibility of using non-invasive specimens for Chlamydia trachomatis testing.

Main Methods:

  • Review of current diagnostic methodologies for Chlamydia trachomatis.
  • Comparison of sensitivity and specificity data for NAATs versus tissue culture.

Related Experiment Videos

  • Evaluation of specimen types compatible with NAATs, including first-catch urine and vaginal swabs.

    • Main Results:

    • Nucleic acid amplification tests (NAATs) are now the preferred diagnostic tests for Chlamydia trachomatis.
    • NAATs demonstrate higher sensitivity compared to traditional tissue culture methods.
    • NAATs can effectively utilize first-catch urine specimens and vaginal swabs, enabling non-invasive sample collection.

    Conclusions:

    • NAATs represent a significant advancement in the diagnosis of Chlamydia trachomatis infections.
    • The enhanced sensitivity and non-invasive nature of NAATs improve patient testing and diagnosis.
    • These tests facilitate easier and more effective screening for genital chlamydial infections.